Stoke Therapeutics announced that its request for an expedited submission of a treatment for severe epilepsy has been postponed by the Food and Drug...
Stoke Therapeutics, Inc., based in Bedford, Massachusetts, has announced significant updates regarding its ongoing clinical trial for zorevunersen, a potential treatment for Dravet syndrome....